Key Takeaways
- Shares of Can-Fite BioPharma (CANF) climbed as high as 65% on Wednesday following the release of Phase 2a data for Namodenoson in patients with advanced pancreatic cancer.
- The trial successfully achieved its primary safety objective among 20 participants who had failed prior standard treatments.
- Among third-line patients, median overall survival surpassed five months, with more than one-third surviving beyond seven months.
- A notable second-line patient remained alive beyond 18 months after initiating Namodenoson treatment — representing the study’s longest-surviving participant.
- The company intends to move forward with a Phase 2b trial combining Namodenoson with chemotherapy agents.
Shares of Can-Fite BioPharma (CANF) experienced a significant rally on Wednesday, climbing as much as 65% after the biotechnology firm disclosed outcomes from its Phase 2a clinical trial evaluating Namodenoson in patients with advanced pancreatic ductal adenocarcinoma (PDAC). Trading activity pushed the stock to approximately $2.97 per share in the wake of the announcement.
The open-label clinical investigation included 20 participants, each having experienced disease progression despite receiving conventional treatment regimens. Among these patients, 14 received Namodenoson as a third-line treatment option, five as second-line therapy, and one as a fourth-line intervention.
The study successfully reached its primary safety objective. Namodenoson demonstrated good tolerability with an adverse event profile aligned with previous clinical investigations.
An updated survival assessment of eight evaluable third-line patients who lived at least two months following treatment initiation revealed median overall survival exceeding five months. This represents a significant benchmark in a malignancy where therapeutic alternatives are severely restricted at advanced stages.
Among this same patient cohort, 62.5% achieved survival of five months or beyond. Additionally, 37.5% lived seven months or longer. At the time of data analysis, two patients remained alive.
The second-line patient group yielded a particularly striking observation. One individual continued to survive more than 18 months following Namodenoson treatment initiation — establishing the longest survival duration recorded in the entire clinical trial.
Principal Investigator’s Perspective
Prof. Salomon Stemmer, who oversees the Phase 2a investigation at the Davidoff Institute of Oncology within Rabin Medical Center in Israel, characterized the Namodenoson monotherapy outcomes as “impressive.”
He emphasized the advantageous safety characteristics and the extended survival observed among a subset of participants as compelling evidence of meaningful biological activity warranting additional exploration. He indicated that the appropriate next phase involves assessing Namodenoson when combined with chemotherapy regimens.
Preclinical research has demonstrated that the compound can amplify the anti-tumor effects of chemotherapeutic drugs in pancreatic cancer experimental models, providing the scientific rationale for this subsequent development stage.
Future Development Plans
Can-Fite intends to progress Namodenoson into a Phase 2b combination trial alongside chemotherapy, leveraging both the Phase 2a clinical outcomes and supportive preclinical findings.
The biotechnology company currently maintains a market capitalization of merely $5.87 million and holds a GF Score of 55 out of 100, indicating modest growth prospects but weak ratings in profitability (1/10) and financial stability (4/10).
No insider transaction activity—either purchases or sales—has been recorded for CANF stock during the preceding 12-month period.
The price-to-sales ratio currently registers at 5.32. For a clinical-stage biotechnology company of this size, investor interest centers primarily on trial outcomes rather than underlying financial metrics.
Get 3 Free Stock Ebooks
Discover top-performing stocks in AI, Crypto, and Technology with expert analysis.
- Top 10 AI Stocks - Leading AI companies
- Top 10 Crypto Stocks - Blockchain leaders
- Top 10 Tech Stocks - Tech giants
